<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.117480</article-id><article-id pub-id-type="publisher-id">ACM-44229</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210700000_94391240.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  Sema 3A对骨重塑影响机制的研究进展
  Research Progress on the Mechanism of the Effect of Sema 3A on Bone Remodeling
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>蔡</surname><given-names>丹霞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>罗</surname><given-names>朋立</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青海大学研究生院，青海 西宁</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>07</month><year>2021</year></pub-date><volume>11</volume><issue>07</issue><fpage>3301</fpage><lpage>3307</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  骨骼是一个新陈代谢活跃的器官，在人的一生中不断重塑。骨重塑是成骨细胞和破骨细胞在成人生长过程中以及骨折等损伤后对骨骼进行重塑和替代的动态、连续过程。骨重塑受多种因素影响，如各种激素、细胞因子、趋化因子、生物机械刺激等。Sema 3A属于Semaphorins家族中的一员，主要通过调节骨髓间充质干细胞、脂肪间充质干细胞、成骨细胞、破骨细胞、感觉神经等多种途径来影响骨重塑。该综述重点总结并介绍Sema 3A对骨重塑影响机制研究的最新进展，以了解Sema 3A在骨骼系统中的作用。
   Bone is an organ with active metabolism, which is constantly reshaped throughout a person’s life. Bone remodeling is a dynamic and continuous process of bone remodeling and substitution of osteoblasts and osteoclasts during adult growth and after fracture and other injuries. Bone remodeling is affected by many factors, such as various hormones, cytokines, chemokines, biomechanical stimulation and so on. Sema 3A is a member of the Semaphorins family, mainly through the regulation of bone marrow mesenchymal stem cells, adipose mesenchymal stem cells, osteoblasts, osteoclasts, sensory nerves and other ways to affect bone remodeling. This review focuses on summarizing and introducing the latest progress in the research on the mechanism of the effect of Sema 3A on bone remodeling in order to understand the role of Sema 3A in the skeletal system.
 
</p></abstract><kwd-group><kwd>Sema 3A，骨重塑，骨髓间充质干细胞，脂肪间充质干细胞，成骨细胞，破骨细胞，感觉神经, Sema 3A</kwd><kwd> Bone Remodeling</kwd><kwd> Bone Marrow Mesenchymal Stem Cells</kwd><kwd> Adipose Mesenchymal Stem Cells</kwd><kwd> Osteoblasts</kwd><kwd> Osteoclasts</kwd><kwd> Sensory Nerves</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>骨骼是一个新陈代谢活跃的器官，在人的一生中不断重塑。骨重塑是成骨细胞和破骨细胞在成人生长过程中以及骨折等损伤后对骨骼进行重塑和替代的动态、连续过程。骨重塑受多种因素影响，如各种激素、细胞因子、趋化因子、生物机械刺激等。Sema 3A属于Semaphorins家族中的一员，主要通过调节骨髓间充质干细胞、脂肪间充质干细胞、成骨细胞、破骨细胞、感觉神经等多种途径来影响骨重塑。该综述重点总结并介绍Sema 3A对骨重塑影响机制研究的最新进展，以了解Sema 3A在骨骼系统中的作用。</p></sec><sec id="s2"><title>关键词</title><p>Sema 3A，骨重塑，骨髓间充质干细胞，脂肪间充质干细胞，成骨细胞，破骨细胞，感觉神经</p></sec><sec id="s3"><title>Research Progress on the Mechanism of the Effect of Sema 3A on Bone Remodeling<sup> </sup></title><p>Danxia Cai, Pengli Luo</p><p>Graduate School of Qinghai University, Xining Qinghai</p><p><img src="//html.hanspub.org/file/61-1572285x4_hanspub.png?20210729084541987" /></p><p>Received: Jun. 26<sup>th</sup>, 2021; accepted: Jul. 19<sup>th</sup>, 2021; published: Jul. 28<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/61-1572285x5_hanspub.png?20210729084541987" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Bone is an organ with active metabolism, which is constantly reshaped throughout a person’s life. Bone remodeling is a dynamic and continuous process of bone remodeling and substitution of osteoblasts and osteoclasts during adult growth and after fracture and other injuries. Bone remodeling is affected by many factors, such as various hormones, cytokines, chemokines, biomechanical stimulation and so on. Sema 3A is a member of the Semaphorins family, mainly through the regulation of bone marrow mesenchymal stem cells, adipose mesenchymal stem cells, osteoblasts, osteoclasts, sensory nerves and other ways to affect bone remodeling. This review focuses on summarizing and introducing the latest progress in the research on the mechanism of the effect of Sema 3A on bone remodeling in order to understand the role of Sema 3A in the skeletal system.</p><p>Keywords:Sema 3A, Bone Remodeling, Bone Marrow Mesenchymal Stem Cells, Adipose Mesenchymal Stem Cells, Osteoblasts, Osteoclasts, Sensory Nerves</p><disp-formula id="hanspub.44229-formula34"><graphic xlink:href="//html.hanspub.org/file/61-1572285x6_hanspub.png?20210729084541987"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/61-1572285x7_hanspub.png?20210729084541987" /> <img src="//html.hanspub.org/file/61-1572285x8_hanspub.png?20210729084541987" /></p></sec><sec id="s5"><title>1. 背景</title><p>骨重塑主要包括两个过程：即成骨细胞性骨形成和破骨细胞性骨吸收。在健康成人中，骨形成和骨吸收在化学及力学等多种因素的调节下保持平衡状态，这种平衡对于维持正常骨量及全身矿物质动态平衡至关重要。相反，骨重塑异常可以导致骨质疏松症、骨坏死等骨骼疾病及血浆钙磷紊乱。以往研究表明骨重塑受多种因子调节，其主要包括甲状旁腺激素(PTH)、骨化三醇、骨形态发生蛋白(BMP)、肿瘤生长因子-β (TGF-β)、和其他激素，如生长激素、糖皮质激素、甲状腺激素和性激素等。近年有研究显示骨来源及神经来源的信号素3A (Sema 3A)均在骨重塑过程中起着重要作用，其可通过调节骨髓间充质干细胞、脂肪间充质干细胞、成骨细胞、破骨细胞、感觉神经等多种途径来影响骨重塑 [<xref ref-type="bibr" rid="hanspub.44229-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.44229-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.44229-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.44229-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.44229-ref5">5</xref>]。本文就Sema 3A对骨重塑机制研究的最新进展作一综述。</p></sec><sec id="s6"><title>2. Sema 3A及其受体</title><sec id="s6_1"><title>2.1. Sema 3A</title><p>信号素(Semaphorins)是一类跨膜或分泌型蛋白，目前至少已发现20余种，根据结构特征和氨基酸序列可将Semaphorin家族成员分为8个亚类，所有信号素均含一个由500个氨基酸组成的sema结构域，介导信号素与相应受体特异性结合 [<xref ref-type="bibr" rid="hanspub.44229-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.44229-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.44229-ref8">8</xref>]。Sema 3A是Semaphorin家族中的一员，属于分泌型蛋白，可来源于成骨细胞 [<xref ref-type="bibr" rid="hanspub.44229-ref2">2</xref>]、骨髓间充质干细胞 [<xref ref-type="bibr" rid="hanspub.44229-ref9">9</xref>]、周围神经元等。以往研究表明Sema 3A在神经再生、血管再生等方面起重要作用 [<xref ref-type="bibr" rid="hanspub.44229-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.44229-ref11">11</xref>]。而最近有研究表明Sema 3A及其受体在骨骼系统中具有重要意义。</p></sec><sec id="s6_2"><title>2.2. Sema 3A相关受体</title><p>神经丛蛋白家族(Plexins)和神经粘连蛋白家族(Neuropilins, Nrps)是信号素的两个主要受体。Plexins是一种跨膜型表面受体，根据其同源性可分为A、B、C和D四个亚类，其中Plexin A是Sema 3A的主要受体 [<xref ref-type="bibr" rid="hanspub.44229-ref7">7</xref>]。Nrps是一种跨膜的细胞表面糖蛋白，包括Nrp-1和Nrp-2 [<xref ref-type="bibr" rid="hanspub.44229-ref12">12</xref>]。Nrps具有较大的胞外结构域、单一的跨膜结构域和较短的细胞质尾巴，与Sema 3A及Plexin A结合的主要是胞外结构域 [<xref ref-type="bibr" rid="hanspub.44229-ref13">13</xref>]。通常Plexin A与Nrp-1或Nrp-2形成信号素受体复合物，而Sema 3A与受体复合物结合形成Sema3A/Nrp/PlexinA配体-受体复合物，从而进行信号转导 [<xref ref-type="bibr" rid="hanspub.44229-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.44229-ref15">15</xref>]。</p></sec></sec><sec id="s7"><title>3. Sema 3A对骨重塑的调节</title><sec id="s7_1"><title>3.1. Sema 3A对成熟骨细胞的影响</title><p>众所周知NO-sGC-cGMP-PKG通路在骨骼动态平衡中起重要作用，该通路从激活一氧化氮合酶(NOS)开始。NOS是细胞内合成一氧化氮(NO)的酶，可升高NO水平，NO水平升高使可溶性鸟苷酸环化酶(sGC)激活增加，从而增加环磷酸鸟苷(cGMP)的水平，cGMP可激活蛋白激酶G (PKG)，而PKG则有防止细胞调亡的作用。</p><p>2012年Nisha Marathe等人发现sGC诱导的cGMP依赖的蛋白激酶G (PKG)活化具有抑制骨细胞凋亡的作用 [<xref ref-type="bibr" rid="hanspub.44229-ref16">16</xref>]。随后Mikihito Hayashi等人 [<xref ref-type="bibr" rid="hanspub.44229-ref3">3</xref>] 发现骨细胞中Sema 3A缺乏或其相关受体缺陷会导致成年小鼠的骨量下降及骨细胞数量减少，体外实验表明sGC激活剂可使成骨细胞系特异性Sema 3A基因敲除小鼠的骨量丢失减少。Sema 3A和sGC激活剂均可增加成熟骨细胞中cGMP的水平，但在未分化的骨细胞中未观察到Sema 3A诱导的cGMP产生，且Sema 3A和sGC激活剂诱导的PKG下游的sGC信号通路的激活(包括ERK、Akt、Vasp)可被PKG抑制剂抑制。以上数据表明，Sema 3A可通过激活sGC-cGMP-PKG信号通路使成熟骨细胞免受调亡。</p></sec><sec id="s7_2"><title>3.2. Sema 3A对骨髓间充质干细胞的影响</title><p>骨髓间充质干细胞(bone marrow mesenchymal stem cells, BMSCs)可来源于许多组织，如骨髓、脂肪组织、牙髓等组织，其中骨髓是骨髓间充质干细胞的原始来源。BMSCs具有多向分化潜能，经过不同的转录因子调节，可以分化为骨细胞、成骨细胞、脂肪细胞和软骨细胞。</p><p>近年有研究表明Sema 3A在骨髓间充质干细胞中显著表达，并促进骨髓间充质干细胞成骨分化 [<xref ref-type="bibr" rid="hanspub.44229-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.44229-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.44229-ref18">18</xref>]。乔桥等人 [<xref ref-type="bibr" rid="hanspub.44229-ref4">4</xref>] 通过体外细胞培养证实了Sema 3A可增加BMSCs成骨相关基因表达(包括I型胶原、碱性磷酸酶、Run相关转录因子2 (RUNX2)、骨形态发生蛋白(BMP)和骨钙素)，促进其向成骨细胞分化，并表明Sema 3A可通过刺激BMSC细胞膜片来增强2型糖尿病大鼠的骨再生能力。Zhaoze Sun等人 [<xref ref-type="bibr" rid="hanspub.44229-ref19">19</xref>] 经过研究发现大肠杆菌脂多糖(LPS)刺激可增加骨髓间充质干细胞炎症因子的表达，建立炎症环境，且LPS可通过激活Wnt/β-catenin信号通路，降低rBMSC的成骨能力；他们还通过在此炎症环境下体外培养大鼠骨髓间充质干细胞(rBMSCs)发现，Sema 3A可减弱LPS降低rBMSC的成骨能力，Sema 3A过表达不仅可以促进rBMSC增殖，还可以通过降低β-catenin的表达来抑制Wnt/β-catenin信号通路，从而减轻LPS介导的成骨分化抑制，并促进rBMSC向成骨细胞分化。</p></sec><sec id="s7_3"><title>3.3. Sema 3A对脂肪间充质干细胞的影响</title><p>脂肪源性的间充质干细胞(adipose mesenchymal stem cells, ASCs)是一种来源于脂肪组织并具有多向分化潜能的成体干细胞。</p><p>Kaixiu Fang等人 [<xref ref-type="bibr" rid="hanspub.44229-ref5">5</xref>] 经过研究发现暴露在Sema 3A刺激下的ASCs形态和增殖能力保持不变，但Sema 3A可通过上调成骨相关基因的表达水平(ALP和COL1A1 mRNA)，增强ASCs的成骨能力。Xiangwei Liu等人 [<xref ref-type="bibr" rid="hanspub.44229-ref9">9</xref>] 通过体外研究表明，Sema 3A在ASCs培养基中过表达显著增强了成骨标志物(ALP、Runx2和Col1a1)的表达和细胞外基质钙沉积，并使碱性磷酸酶活性增强，Sema 3A基因转染的ASCs骨基质分泌增多。以上数据表明Sema 3A可诱导ASCs产生BMSCs表型，Sema 3A过表达可使脂肪间充质干细胞向成骨细胞转变。为了进一步阐明Sema 3A如何将ASCs重新编程为BMSCs样表型的分子机制，他们研究了与成骨分化和成脂分化密切相关的Wnt/β-catenin信号通路。结果表明，Sema 3A可使ASCs细胞核内β-catenin表达明显增强，此外，一些上下游的Wnt途径基因(如Wnt3a、Wnt10a和Axin2)表达也增加，这些数据表明Sema 3A通过调控多个Wnt途径基因来激活Wnt通路，使ASCs在一定程度上被重新编程为具有BMSCs表型，促进其成骨分化，增加其成骨能力，从而起到有效的成骨诱导剂的作用。综上所述，Sema 3A通过激活Wnt通路将ASCs重新编程为具有BMSCs表型，并使其向成骨表型转化来促进体内骨再生。</p></sec><sec id="s7_4"><title>3.4. Sema 3A对成骨细胞的影响</title><p>成骨细胞主要起源于骨髓间充质干细胞(bone marrow stromal cells, BMSCs)，可通过合成细胞外基质蛋白形成新骨，在骨重塑方面起着重要作用。</p><p>Wnt蛋白是一个分泌蛋白家族，可在细胞生长、分化、功能和死亡等许多方面进行调节。在Wnts激活的信号通路中，Wnt/β-catenin信号通路可通过一系列机制增加骨量，包括刺激成骨细胞复制、诱导成骨细胞生成、抑制成骨细胞和骨细胞凋亡等。Wnt/β-catenin信号通路的激活可保护β-catenin不被磷酸化，而未被磷酸化的β-catenin从胞浆移位并聚集在细胞核中，然后与T细胞因子/淋巴增强因子结合，形成转录因子复合体，促进成骨细胞特异性基因的表达，增加其分化 [<xref ref-type="bibr" rid="hanspub.44229-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.44229-ref21">21</xref>]。</p><p>Mikihito Hayashi等人 [<xref ref-type="bibr" rid="hanspub.44229-ref2">2</xref>] 对Sema 3A基因敲除小鼠的颅骨细胞进行基因表达谱分析显示其Wnt信号通路和Wnt相关信号通路的基因集表达显著下调，且通过转录形成β-catenin的mRNA表达下降及Wnt诱导的β-catenin 核聚集受到抑制。Sema 3A信号通路通过FARP2可诱导小G蛋白rac1活化，而rac1可促进β-catenin核聚集 [<xref ref-type="bibr" rid="hanspub.44229-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.44229-ref22">22</xref>]。与野生型对照细胞相比，Sema 3A基因敲除的小鼠颅骨细胞给予Wnt处理后rac的激活显著降低，但给予Sema 3A处理后，可促进rac激活从而促进β-catenin核转移 [<xref ref-type="bibr" rid="hanspub.44229-ref2">2</xref>]。Sevin&#231; Kenan等人 [<xref ref-type="bibr" rid="hanspub.44229-ref23">23</xref>] 也通过实验表明局部应用Sema 3A可使骨形成活性增强，且Sema 3A可增强β-catenin的表达。Mikihito Hayashi等人 [<xref ref-type="bibr" rid="hanspub.44229-ref2">2</xref>] 还发现Sema 3A通过与其相应受体Nrp1结合来促进成骨细胞分化。综上所述，Sema 3A对成骨细胞分化影响机制可能为Sema 3A与其受体Nrp1结合后激活Wnt/β-catenin信号通路及促进rac激活从而增加β-catenin核转移来促进骨细胞分化。</p></sec><sec id="s7_5"><title>3.5. Sema 3A对破骨细胞的影响</title><p>骨髓来源的单核/巨噬细胞前体细胞(Bone marrow-derived Monocyte/m-acrophage precursor cells, BMMs)是破骨细胞的前体细胞。成骨细胞产生的核因子受体激活剂-β配体(RANKL)和巨噬细胞集落刺激因子(M-CSF)是刺激破骨细胞分化的关键因子，其分别与BMMs表达的c-FMS (M-CSF受体)和RANK (RANKL受体)结合可使BMMs分化为破骨细胞，而成骨细胞产生的骨保护素(OPG)则与RANKL结合来抑制破骨细胞生成 [<xref ref-type="bibr" rid="hanspub.44229-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.44229-ref25">25</xref>]。</p><p>Ar&#225;nzazu Mediero等人 [<xref ref-type="bibr" rid="hanspub.44229-ref26">26</xref>] 通过研究表明Sema 3A可抑制破骨细胞前体细胞向破骨细胞分化。K Yang等人 [<xref ref-type="bibr" rid="hanspub.44229-ref27">27</xref>] 也表示信号素3A基因治疗可显著增加成骨细胞的数量和活性，减少破骨细胞的数量，最终抑制骨质疏松症小鼠的骨丢失。</p><p>Mikihito Hayashi等人 [<xref ref-type="bibr" rid="hanspub.44229-ref2">2</xref>] 通过研究表明Sema 3A通过与其受体Nrp1结合来抑制破骨细胞分化。有研究表明PlexinA1通过形成PlexinA1-TREM2-DAP12复合物与Sema 6D结合，激活ITAM信号，从而促进破骨细胞分化 [<xref ref-type="bibr" rid="hanspub.44229-ref28">28</xref>]。然而Nrp1可与TREM2竞争结合PlexinA1，形成PlexinA1-Nrp1受体复合物并与Sema 3A结合形成Sema3A/Nrp-1/PlexinA1配体–受体复合物，抑制破骨细胞分化 [<xref ref-type="bibr" rid="hanspub.44229-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.44229-ref6">6</xref>]。RANKL可通过下调Nrp1使PlexinA1从PlexinA1-Nrp1复合物中释放出来，从而促进Plexin1-TREM2-DAP12复合物的形成来诱导破骨细胞分化；而Sema 3A处理可诱导Nrp1内化并抑制RANKL的表达，对抗RANKL诱导的Nrp1下调，从而维持PlexinA1-Nrp1复合物形成来平衡RANKL作用，抑制破骨细胞分化 [<xref ref-type="bibr" rid="hanspub.44229-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.44229-ref23">23</xref>]。</p></sec><sec id="s7_6"><title>3.6. Sema 3A通过神经调节骨重塑</title><p>骨组织上神经分布密集，有研究表明中枢及外周神经系统均参与调节骨重塑 [<xref ref-type="bibr" rid="hanspub.44229-ref29">29</xref>]。</p><p>Toru Fukuda等人 [<xref ref-type="bibr" rid="hanspub.44229-ref1">1</xref>] 提出神经元来源的Sema 3A不但对正常神经系统发育具有重要作用，还通过调节感觉神经纤维间接影响骨重塑。他们经过研究证明骨骼微环境中Sema 3A的水平是由支配骨骼的感觉神经系统及骨细胞共同决定的，神经元特异性Sema 3A敲除的小鼠表现出低骨量表型，且骨量的减少与感觉神经的减少一致。因此感觉神经纤维的异常可能是导致神经元特异性Sema 3A敲除小鼠骨量异常的原因。</p><p>以往有研究表明，坐骨神经提供支配股骨和胫骨的神经纤维，单侧坐骨神经切除术可导致废用性骨质疏松，但其机制尚不明确 [<xref ref-type="bibr" rid="hanspub.44229-ref30">30</xref>] [<xref ref-type="bibr" rid="hanspub.44229-ref31">31</xref>]。Xinlong Ma等人 [<xref ref-type="bibr" rid="hanspub.44229-ref32">32</xref>] 通过试验研究表明，与假手术组相比，单侧坐骨神经切除术后的大鼠股骨远端骨密度明显降低、同侧胫骨中Sema 3A mRNA、β-catenin mRNA、Nrp1 mRNA表达降低，且Sema 3A蛋白、活性β-catenin蛋白水平也降低。如前所述，Sema 3A通过与Nrp1结合激活Wnt/β-catenin信号通路从而诱导成骨细胞分化，而β-catenin是Wnt/β-catenin信号级联中的一个重要分子，故坐骨神经切除术后大鼠Sema 3A及活性β-catenin蛋白水平降低，可导致Wnt/β-catenin信号通路激活减弱，成骨细胞分化减少，从而参与废用性骨质疏松症的发生发展。</p></sec><sec id="s7_7"><title>3.7. 其他</title><p>骨肉瘤是起源于间质细胞的恶性成骨性肿瘤，可发生骨溶解和异位“编织”骨形成等骨骼并发症。近年有研究表明骨肉瘤细胞系过度表达Nrp1和Nrp2，且表达程度与肿瘤的进展及预后有关 [<xref ref-type="bibr" rid="hanspub.44229-ref33">33</xref>] [<xref ref-type="bibr" rid="hanspub.44229-ref34">34</xref>]。还有研究表明Nrp2在人骨肉瘤细胞系中可抑制肿瘤的生长，在小鼠中可减少肺转移 [<xref ref-type="bibr" rid="hanspub.44229-ref35">35</xref>]。Dani&#235;lle de Ridder等人经过研究证明人重组Sema 3A可抑制骨肉瘤细胞的迁移、成骨和溶骨功能，骨肉瘤来源的Sema 3A可降低骨肉瘤细胞引起异位骨形成的能力。他们还证明外源性和肿瘤来源的Sema 3A在体外均可抑制骨肉瘤细胞系及RANKL诱导的破骨细胞的形成 [<xref ref-type="bibr" rid="hanspub.44229-ref36">36</xref>]，但具体机制尚不明确。</p><p>骨折骨痂中血管的及时形成对加速骨再生至关重要。有研究表明Sema 3A过表达可抑制血管生成 [<xref ref-type="bibr" rid="hanspub.44229-ref37">37</xref>]，而HIF1α可促进血管生成 [<xref ref-type="bibr" rid="hanspub.44229-ref38">38</xref>]。Li等人 [<xref ref-type="bibr" rid="hanspub.44229-ref37">37</xref>] 通过实验表明Sema 3A-HIF1α共表达的多能干细胞来源的间充质干胞(IPSC-MSCs)在体外具有良好的成骨和血管分化能力，可促进新生骨和胶原纤维的形成进而促进小鼠颅骨缺损修复。Li等人 [<xref ref-type="bibr" rid="hanspub.44229-ref39">39</xref>] 还通过研究表明Sema 3A单独过表达虽可促进IPSC-MSCs的成骨分化，但抑制细胞存活。而Sema 3A-HIF1α共过表达不仅能促进其成骨分化，还能提高IPSC-MSCs的存活率，但其具体机制尚不明确。</p></sec></sec><sec id="s8"><title>4. 小结</title><p>Sema 3A可由多种细胞表达，其受体广泛分布于骨骼系统、神经系统，Sema 3A与其相应受体结合可产生多种作用。近年来Sema 3A在骨骼系统中的作用成为研究热点。众多学者经过研究表明，Sema 3A与其相关受体结合后通过保护成熟骨细胞免受调亡、促进成骨细胞分化、抑制破骨细胞分化、促进rBMSC成骨分化、将ASCs重新编程为具有BMSCs表型及调节感觉神经等多种途径参与骨重塑。还有研究表明Sema 3A有抑制骨肉瘤的转移、溶骨等作用，Sema 3A-HIF1α共过表达可使IPSC-MSCs更好的成骨分化及血管分化，但其具体机制需要我们进一步研究。由此可见，Sema 3A可能是一种骨质疏松及骨肉瘤等骨病的新型治疗剂。</p></sec><sec id="s9"><title>文章引用</title><p>蔡丹霞,罗朋立. Sema 3A对骨重塑影响机制的研究进展Research Progress on the Mechanism of the Effect of Sema 3A on Bone Remodeling[J]. 临床医学进展, 2021, 11(07): 3301-3307. https://doi.org/10.12677/ACM.2021.117480</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44229-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Fukuda, T., et al. (2013) Corrigendum: Sema3A Regulates Bone-Mass Accrual through Sensory Innervations. Nature, 497, 490-493. &lt;br&gt;https://doi.org/10.1038/nature12115</mixed-citation></ref><ref id="hanspub.44229-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Hayashi, M., Nakashima, T., Taniguchi, M., et al. (2012) Osteoprotection by Semaphorin 3A. Nature, 485, 69-74.  
&lt;br&gt;https://doi.org/10.1038/nature11000</mixed-citation></ref><ref id="hanspub.44229-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Mikihito, H., et al. (2019) Autoregulation of Osteocyte Sema3A Orchestrates Estrogen Action and Counteracts Bone Aging. Cell Metabolism, 29, 627-637. &lt;br&gt;https://doi.org/10.1016/j.cmet.2018.12.021</mixed-citation></ref><ref id="hanspub.44229-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">乔桥, 宋应亮, 李风兰. 信号素3A刺激的干细胞膜片对2型糖尿病大鼠骨再生作用的研究[J]. 中华口腔医学杂志, 2018, 53(5): 333-338.</mixed-citation></ref><ref id="hanspub.44229-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Fang, K., Song, W., Wang, L., et al. (2016) Semaphorin 3A-Modified Adipose-Derived Stem Cell Sheet May Improve Osseointegration in a Type 2 Diabetes Mellitus Rat Model. Molecular Medicine Reports, 14, 2449-2456.  
&lt;br&gt;https://doi.org/10.3892/mmr.2016.5568</mixed-citation></ref><ref id="hanspub.44229-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Semaphorin Nomenclature Committee (1999) Unified Nomenclature for the Semaphorins/Collapsins. Cell, 97, 551-552.  
&lt;br&gt;https://doi.org/10.1016/S0092-8674(00)80766-7</mixed-citation></ref><ref id="hanspub.44229-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Janssen, B.J., Robinson, R.A., Pérez-Brangulí, F., et al. (2010) Structural Basis of Semaphorin-Plexin Signalling. Nature, 467, 1118-1122. &lt;br&gt;https://doi.org/10.1038/nature09468</mixed-citation></ref><ref id="hanspub.44229-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Feiner, L., Koppel, A.M., Kobayashi, H., et al. (1997) Secreted Chick Semaphorins Bind Recombinant Neuropilin with Similar Affinities but Bind Different Subsets of Neurons in Situ. Neuron, 19, 539-545.  
&lt;br&gt;https://doi.org/10.1016/S0896-6273(00)80370-0</mixed-citation></ref><ref id="hanspub.44229-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Liu, X., Tan, N., Zhou, Y., et al. (2016) Semaphorin 3A Shifts Adipose Mesenchymal Stem Cells towards Osteogenic Phenotype and Promotes Bone Regeneration in Vivo. Stem Cells International, 2016, Article ID: 2545214.  
&lt;br&gt;https://doi.org/10.1155/2016/2545214</mixed-citation></ref><ref id="hanspub.44229-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Min, Z., Qiang, Z., Luo, Y., et al. (2018) Semaphorin3A Induces Nerve Regeneration in the Adult Cornea—A Switch from Its Repulsive Role in Development. PLoS ONE, 13, e0191962. &lt;br&gt;https://doi.org/10.1371/journal.pone.0191962</mixed-citation></ref><ref id="hanspub.44229-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Adi, S.D., Eiza, N., Bejar, J., et al. (2019) Semaphorin 3A Is Effective in Reducing Both Inflammation and Angiogenesis in a Mouse Model of Bronchial Asthma. Frontiers in Immunology, 10, 550.  
&lt;br&gt;https://doi.org/10.3389/fimmu.2019.00550</mixed-citation></ref><ref id="hanspub.44229-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Rochlin, M.W. and Farbman, A.I. (1998) Trigeminal Ganglion Axons Are Repelled by Their Presumptive Targets. Journal of Neuroscience, 18, 6840-6852. &lt;br&gt;https://doi.org/10.1523/JNEUROSCI.18-17-06840.1998</mixed-citation></ref><ref id="hanspub.44229-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Janssen, B.J.C., Malinauskas, T., Weir, G.A., et al. (2012) Neuropilins Lock Secreted Semaphorins onto Plexins in a Ternary Signaling Complex. Nature Structural &amp; Molecular Biology, 19, 1293-1299.  
&lt;br&gt;https://doi.org/10.1523/JNEUROSCI.18-17-06840.1998</mixed-citation></ref><ref id="hanspub.44229-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Kruger, R.P., Aurandt, J. and Guan, K.L. (2005) Semaphorins Command Cells to Move. Nature Reviews Molecular Cell Biology, 6, 789-800. &lt;br&gt;https://doi.org/10.1038/nrm1740</mixed-citation></ref><ref id="hanspub.44229-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Yazdani, U. and Terman, J.R. (2006) The Semaphorins. Genome Biology, 7, 211.  
&lt;br&gt;https://doi.org/10.1186/gb-2006-7-3-211</mixed-citation></ref><ref id="hanspub.44229-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Marathe, N., Rangaswami, H., Zhuang, S., et al. (2012) Pro-Survival Effects of 17β-Estradiol on Osteocytes Are Mediated by Nitric Oxide/cGMP via Differential Actions of cGMP-Dependent Protein Kinases I and II. Journal of Biological Chemistry, 287, 978-988. &lt;br&gt;https://doi.org/10.1074/jbc.M111.294959</mixed-citation></ref><ref id="hanspub.44229-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Liu, L., Wang, J., Song, X., et al. (2018) Semaphorin 3A Promotes Osteogenic Differentiation in Human Alveolar Bone Marrow Mesenchymal Stem Cells. Experimental and Therapeutic Medicine, 15, 3489-3494.  
&lt;br&gt;https://doi.org/10.3892/etm.2018.5813</mixed-citation></ref><ref id="hanspub.44229-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Tian, T., Tang, K., Wang, A., et al. (2019) The Effects of Sema 3A Overexpression on the Proliferation and Differentiation of Rat Gingival Mesenchymal Stem Cells in the LPS-Induced Inflammatory Environment. International Journal of Clinical and Experimental Pathology, 12, 3710-3718.</mixed-citation></ref><ref id="hanspub.44229-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Sun, Z., Yan, K., Liu, S., et al. (2021) Semaphorin 3A Promotes the Osteogenic Differentiation of Rat Bone Marrow-Derived Mesenchymal Stem Cells in Inflammatory Environments by Suppressing the Wnt/β-Catenin Signaling Pathway. Journal of Molecular Histology. &lt;br&gt;https://doi.org/10.1007/s10735-020-09941-1</mixed-citation></ref><ref id="hanspub.44229-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Tian, J., He, H. and Lei, G. (2014) Wnt/β-Catenin Pathway in Bone Cancers. Tumor Biology, 35, 9439-9445.  
&lt;br&gt;https://doi.org/10.1007/s13277-014-2433-8</mixed-citation></ref><ref id="hanspub.44229-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Krishnan, V., Bryant, H.U. and Macdougald, O.A. (2006) Regulation of Bone Mass by Wnt Signaling. Journal of Clinical Investigation, 116, 1202-1209. &lt;br&gt;https://doi.org/10.1172/JCI28551</mixed-citation></ref><ref id="hanspub.44229-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Wu, X., Tu, X., Joeng, K.S., Hilton, M.J., et al. (2008) Rac1 Activation Controls Nuclear Localization of Beta-Catenin during Canonical Wnt Signaling. Cell, 133, 340-353. &lt;br&gt;https://doi.org/10.1016/j.cell.2008.01.052</mixed-citation></ref><ref id="hanspub.44229-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Kenan, S., Onur, Ö.D., Solakoğlu, S., et al. (2019) Investigation of the Effects of Semaphorin 3A on New Bone Formation in a Rat Calvarial Defect Model. Journal of Cranio-Maxillofacial Surgery, 47, 473-483.  
&lt;br&gt;https://doi.org/10.1016/j.jcms.2018.12.010</mixed-citation></ref><ref id="hanspub.44229-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Yamashita, T., Takahashi, N. and Udagawa, N. (2012) New Roles of Osteoblasts Involved in Osteoclast Differentiation. World Journal of Orthopedics, 3, 175-181. &lt;br&gt;https://doi.org/10.5312/wjo.v3.i11.175</mixed-citation></ref><ref id="hanspub.44229-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Simonet, W.S., Lacey, D.L., Dunstan, C.R., et al. (1997) Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density. Cell, 89, 309-319. &lt;br&gt;https://doi.org/10.1016/S0092-8674(00)80209-3</mixed-citation></ref><ref id="hanspub.44229-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Mediero, A., Wilder, T., Shah, L., et al. (2018) Adenosine A2A Receptor (A2AR) Stimulation Modulates Expression of Semaphorins 4D and 3A, Regulators of Bone Homeostasis. The FASEB Journal, 32, 3487-3501.  
&lt;br&gt;https://doi.org/10.1016/S0092-8674(00)80209-3</mixed-citation></ref><ref id="hanspub.44229-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Yang, K., Miron, R.J., Bian, Z., et al. (2018) A Bone-Targeting Drug-Delivery System Based on Semaphorin 3A Gene Therapy Ameliorates Bone Loss in Osteoporotic Ovariectomized Mice. Bone, 114, 40-49.  
&lt;br&gt;https://doi.org/10.1016/j.bone.2018.06.003</mixed-citation></ref><ref id="hanspub.44229-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Takegahara, N., Takamatsu, H., Toyofuku, T., et al. (2006) Plexin-A1 and Its Interaction with DAP12 in Immune Responses and Bone Homeostasis. Nature Cell Biology, 8, 615-622. &lt;br&gt;https://doi.org/10.1038/ncb1416</mixed-citation></ref><ref id="hanspub.44229-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Karsenty, G. and Ferron, M. (2012) The Contribution of Bone to Whole-Organism Physiology. Nature, 481, 314-320.  
&lt;br&gt;https://doi.org/10.1038/nature10763</mixed-citation></ref><ref id="hanspub.44229-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Kingery, W.S., Offley, S.C., Guo, T.Z., et al. (2003) A Substance P Receptor (NK1) Antagonist Enhances the Widespread Osteoporotic Effects of Sciatic Nerve Section. Bone, 33, 927-936. &lt;br&gt;https://doi.org/10.1016/j.bone.2003.07.003</mixed-citation></ref><ref id="hanspub.44229-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Komori, T. (2015) Animal Models for Osteoporosis. European Journal of Pharmacology, 759, 287-294.  
&lt;br&gt;https://doi.org/10.1016/j.ejphar.2015.03.028</mixed-citation></ref><ref id="hanspub.44229-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Ma, X., Lv, J., Sun, X., et al. (2016) Naringin Ameliorates Bone Loss Induced by Sciatic Neurectomy and Increases Semaphorin 3A Expression in Denervated Bone. Scientific Reports, 6, Article No. 4562.  
&lt;br&gt;https://doi.org/10.1038/srep24562</mixed-citation></ref><ref id="hanspub.44229-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, H., Cai, H., Tang, M., et al. (2014) Neuropilin-1 Is Overexpressed in Osteosarcoma and Contributes to Tumor Progression and Poor Prognosis. Clinical and Translational Oncology, 16, 732-738.  
&lt;br&gt;https://doi.org/10.1007/s12094-013-1141-y</mixed-citation></ref><ref id="hanspub.44229-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Boro, A., Arlt, M.J., Lengnick, H., et al. (2015) Prognostic Value and in Vitro Biological Relevance of Neuropilin 1 and Neuropilin 2 in Osteosarcoma. American Journal of Translational Research, 7, 640-653.</mixed-citation></ref><ref id="hanspub.44229-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Ji, T., Guo, Y., Kim, K., et al. (2015) Neuropilin-2 Expression Is Inhibited by Secreted Wnt Antagonists and Its Down-Regulation Is Associated with Reduced Tumor Growth and Metastasis in Osteosarcoma. Molecular Cancer, 14, 86. &lt;br&gt;https://doi.org/10.1186/s12943-015-0359-4</mixed-citation></ref><ref id="hanspub.44229-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">de Ridder, D., Marino, S., Bishop, R.T., et al. (2018) Bidirectional Regulation of Bone Formation by Exogenous and Osteosarcoma-Derived Sema3A. Scientific Reports, 8, Article No. 6877. &lt;br&gt;https://doi.org/10.1038/s41598-018-25290-2</mixed-citation></ref><ref id="hanspub.44229-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Li, J., Wang, T., Li, C., et al. (2020) Sema3A and HIF1α Co-Overexpressed iPSC-MSCs/HA Scaffold Facilitates the Repair of Calvarial Defect in a Mouse Model. Journal of Cellular Physiology, 235, 6754-6766.  
&lt;br&gt;https://doi.org/10.1002/jcp.29569</mixed-citation></ref><ref id="hanspub.44229-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Ou, M., Sun, X., Liang, J., et al. (2017) A Polysaccharide from Sargassum thunbergii Inhibits Angiogenesis via Downregulating MMP-2 Activity and VEGF/HIF-1α Signaling. International Journal of Biological Macromolecules, 94, 451-458. &lt;br&gt;https://doi.org/10.1016/j.ijbiomac.2016.10.046</mixed-citation></ref><ref id="hanspub.44229-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Li, J.Y., Wang, T.T., Li, C., et al. (2020) Semaphorin 3A-Hypoxia Inducible Factor 1 Subunit Alpha Co-Overexpression Enhances the Osteogenic Differentiation of Induced Pluripotent Stem Cells-Derived Mesenchymal Stem Cells in Vitro. Chinese Medical Journal, 133, 301-309. &lt;br&gt;https://doi.org/10.1097/CM9.0000000000000612</mixed-citation></ref></ref-list></back></article>